Related Experiment Video
Updated: Aug 14, 2026
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Future perspectives in the medical treatment of endometriosis
Simone Ferrero1, Luiza Helena Abbamonte, Paola Anserini
1Department of Obstetrics and Gynaecology, San Martino Hospital, University of Genoa, Genoa, Italy. simone.ferrero@fastwebnet.it
Unlabelled:
In the last few years, our understanding of the pathogenesis of endometriosis at the cellular and molecular levels has improved significantly. This may give us the opportunity to use new, specific agents for the treatment of this disorder. Despite the effectiveness of the available treatments, novel therapeutic strategies may improve our ability to eliminate endometriotic lesions when present and to prevent the recurrence of endometriosis after surgical treatment. This review focuses on the new, experimental approaches to the medical treatment of endometriosis and its symptoms. The blockage of aromatase activity in endometriotic lesions with an aromatase inhibitor may represent a new step in the medical treatment of endometriosis. Preliminary clinical studies have demonstrated the efficacy of third-generation nonsteroidal aromatase inhibitors (ie, anastrozole and letrozole) in reducing the intensity of pain symptoms associated with the presence of endometriosis. The new selective progesterone receptor modulators may represent a valid hormonal treatment option. Therapeutic manipulation of the immune system through TNFalpha inhibitors may be beneficial in women with endometriosis. New pharmaceutical agents affecting inflammation, angiogenesis, and matrix metalloproteinase activity may prevent or inhibit the development of endometriosis. Further clinical trials may determine if these new therapies are superior to current medical treatment strategies for endometriosis.
Target Audience:
Obstetricians & Gynecologists, Family Physicians Learning.
Objectives:
After completion of this article, the reader should be able to describe the new experimental medical treatments of endometriosis, state that the clinical use of nonsteroidal aromatase inhibitors for endometriosis appears to be efficacious but is based on preliminary clinical data, and recall that the drugs used for endometriosis in the future may include manipulation of the immune system.
Insights
New treatments for endometriosis show promise, including aromatase inhibitors and immune system modulation. These experimental therapies aim to eliminate lesions and prevent recurrence, offering hope beyond current options.
Area of Science:
- Cellular and molecular understanding of endometriosis pathogenesis has advanced.
- This progress enables the development of novel, targeted therapeutic agents.
Background:
- Current endometriosis treatments are effective but have limitations.
- Novel strategies are needed to eliminate existing lesions and prevent recurrence post-surgery.
Purpose of the Study:
- To review emerging experimental medical treatments for endometriosis.
- To highlight new therapeutic approaches targeting endometriosis symptoms and pathogenesis.
Main Methods:
- Review of current literature on novel endometriosis treatments.
- Focus on experimental approaches including aromatase inhibitors, selective progesterone receptor modulators, and immune system modulation.
Main Results:
- Third-generation nonsteroidal aromatase inhibitors (anastrozole, letrozole) show preliminary efficacy in reducing endometriosis-associated pain.
- Selective progesterone receptor modulators offer a potential hormonal treatment option.
- TNFalpha inhibitors and agents targeting inflammation, angiogenesis, and matrix metalloproteinase activity are under investigation.
Conclusions:
- Experimental therapies like aromatase inhibitors and immune modulators represent promising new avenues for endometriosis treatment.
- Further clinical trials are necessary to validate the efficacy and superiority of these novel treatments compared to existing strategies.
